Posters

Feb 20

Stemina to Present Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2017

Feb 20, 2017
Stemina Biomarker Discovery will be well represented at the Society of Toxicology’s 56th Annual Meeting and ToxExpo. In addition to participating in SOT as an exhibitor (booth 2506), Stemina’s Jessica Palmer, Associate Director of Toxicology, will present new research in two sessions: Poster session: Monday, March 13th | 9:30 AM – 12:45 PM | P331

Read more
May 16

Evidence for Metabolomic Phenotypes Based on Analysis of Plasma from the Autism Phenome Project Cohort

May 16, 2016
Metabolomics can identify predictive and actionable biomarker profiles from a child’s inherited biochemistry as well as the interactions of the gut microbiome with dietary and environmental factors that may contribute to ASD. Identification of metabolic profiles in children with ASD creates an opportunity to develop metabolic based diagnostics that enable early diagnosis and elucidate biochemical changes associated with

Read more
Apr 1

Combination of a Human Pluripotent Stem Cell and Zebrafish Assay to Predict The Developmental Toxicity of Chemicals

Apr 1, 2016
The primary alternative in vitro-ex vivo assays used to evaluate developmental toxicity potential are cellular models using pluripotent stem cells and embryo-based models. Multiple industries are employing these types of assays to screen for toxicity potential and enable selection and prioritization of the most promising chemicals for further development, effectively reducing the number animals required

Read more
Mar 23

A Metabolic Profile of Autism Spectrum Disorder from Autism Phenome Project Patient Plasma

Mar 23, 2016
We The diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. Patients can be reliably diagnosed through behavioral testing at about 2 years of age. However, in the United States the average age of diagnosis is around 4 years. Identifying metabolic biomarkersignatures of ASD from blood

Read more
Feb 20

A Biomarker-Based Human Stem Cell Assay Applied for Ranking a Retinoid Series Based on Relative Developmental Toxicity Potential

Feb 20, 2016
We previously developed an in vitro, biomarker-based, human induced pluripotent stem (iPS) cell-based assay to screen compounds for developmental toxicity. The assay measures changes in two amino acids (ornithine and cystine) involved in cell proliferation and differentiation. This assay (devTOXqP) is currently being applied as an alternative model to aid in ongoing worldwide efforts to

Read more
Jan 3

Evaluation of 1066 Toxcast Chemicals in a Human Sem Cell Assay for Developmental Toxicity

Jan 3, 2016
EPA’s ToxCast program has generated data on a battery of 821 in vitro endpoints for 1066 compounds including pharmaceuticals, natural products, pesticidal active ingredients, consumer use chemicals and industrial ingredients. To increase the diversity of in vitro assays used to assess developmental toxicity, the ToxCast library was evaluated in the Stemina ‘devTOX quickPREDICT’ (qP) platform.

Read more
Dec 15

Toward Validation of a Human In Vitro Assay for Developmental Toxicity Assessment

Dec 15, 2015
Innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animal models are required for the REACH initiative (Europe) and Tox21 initiative (US) to evaluate thousands of chemicals for safety. We have created a predictive, human in vitro pluripotent stem cell based developmental toxicity assay that can reduce costs, animal and

Read more
Nov 23

A Biomarker Based Developmental Toxicity Screen Using Human Induced Pluripotent Stem Cells For Compound Prioritization

Nov 23, 2015
Development of innovative in vitro toxicity screening assays aimed at reducing or replacing the use of animal models in compound safety testing is critical to meet the safety requirements for multiple industries. The current initiatives in Europe (Registration, Evaluation, and Authorization of Chemicals, REACH) and the United States (Tox21) to screen thousands of chemicals currently

Read more
Oct 21

Establishment and Assessment of a New Human Embryonic Stem Cell Based Biomarker Assay for Developmental Toxicity Screening

Oct 21, 2015
Application of more predictive developmental toxicity screens would aid in reducing the prevalence of birth defects and increase pharmaceutical and chemical safety worldwide. Human embryonic stem (hES) cell technology provides an opportunity for innovative and robust alternative in vitro model systems. Previously, we used high resolution mass spectrometry (HRMS) based metabolomics to discover and test

Read more
Jul 11

Development of a Targeted Biomarker Assay to Predict Developmental Toxicity Using Induced Pluripotent Stem Cells

Jul 11, 2015
Assessment of the developmental toxicity potential of new chemicals is both resource intensive and time consuming. Large numbers of laboratory animals are required and the predictive value of these decades-old tests has been challenged. Availability of more predictive developmental toxicity screens would reduce costs and increase pharmaceutical and chemical safety. A small molecule biomarker-based in

Read more
May 18

A Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells

May 18, 2015
Birth defects are the largest cause of infant morbidity and mortality in the United States. Teratogens, defined as substances that cause fetal abnormalities during development, are responsible for 5-10% of all birth defects. The application of more predictive developmental toxicity screens would reduce the prevalence of birth defects and increase pharmaceutical and chemical safety. Human

Read more
Mar 8

A High Throughput Metabolite-Based Biomarker Approach to Predict Developmental Toxicity Using Human Embryonic Stem Cells

Mar 8, 2015
Birth defects are the largest cause of infant morbidity and mortality in the United States. Teratogens, defined as substances that cause one or more fetal abnormalities during development, are responsible for 5-10% of all birth defects. Availability of more predictive developmental toxicity screens would increase pharmaceutical and chemical safety and could reduce the prevalence of

Read more
Oct 4

Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Pluripotent Stem Cell-Derived Cardiomyocytes

Oct 4, 2014
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for the withdrawal of 28% of FDA-approved drugs from the market. The development of better screening assays to predict cardiotoxicity is needed to enable the placement of safer drugs in the market and reduce adverse effects. Current

Read more
Jan 23

Key Metabolic Pathway Changes in Human Embryonic Stem Cells Exposed to Methyl Parathion and Methyl Paraoxon

Jan 23, 2014
Toxic industrial chemicals (TICs) represent a threat to soldiers, first responders and other civilians. One class of toxic industrial chemicals, pesticides, is particularly accessible and used widely in crop, industrial, and home applications. For many pesticides, including methyl parathion (MP), there is incomplete and sometimes conflicting information regarding the basic molecular toxicological consequences of exposure

Read more
Nov 3

An Alternative Developmental Toxicity Screening Capability

Nov 3, 2013
Birth defects are the leading cause of infant mortality but approximately 70%of birth defects have no known cause (CDC, 2005). Between 2 and 3% of birth defects are caused by teratogens, or substances that cause birth defects (Finnell, 1999). Pharmaceutical companies screen for developmental toxicity using animal models, yet these screens are only as little

Read more
Sep 25

Metabolomics Based Comparison of Human Embryonic and Induced Pluripotent Stem Cells to Predict Developmental Toxicity

Sep 25, 2013
Induced pluripotent stem (iPS) cells are derived from the genetic manipulation of somatic cells. These cells are being investigated for use in place of hES cells due to the moral, ethical and political controversies that surround them. Human iPS cells are phenotypically and genetically similar to hES cells in many respects (i.e. morphology, proliferation, gene

Read more
Jul 31

A Laboratory Information Management System (LIMS) for High-Throughput LC-MS Metabolomics-based Biomarker Discovery

Jul 31, 2013
SteminaLIMS is a web-based laboratory management tool specifically designed to streamline the processes involved with metabolomics based biomarker discovery. The SteminaLIMS manages the entire stream of textual, numerical, statistical and graphical data including project information sample preparation and metadata, mass spectrometry data acquisition and analysis, file conversion, peak picking, statistical analysis, annotation, and small molecule

Read more
Jun 19

Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Jun 19, 2013
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for the withdrawal of 28% of FDA-approved drugs from the market. The development of better screening assays to predict cardiotoxicity is needed to enable the placement of safer drugs in the market and reduce adverse effects. Current

Read more
Apr 11

Discovery of Cancer Stem Cell Biomarkers Using Metabolomics

Apr 11, 2013
Stemina Biomarker Discovery, Inc. has engaged in a study to discover metabolomic biomarkers that are potential indicators of drug efficacy against cancer stem cells (CSCs) for the establishment of novel drug screening assays. The primary cellular target used in this screen was cancer stem cells derived from glioblastoma multiforme (GBM), brain tumor stem cells (BTSCs),

Read more
Feb 1

Predictive Metabolism Based Model of Cardiomyopathy Using Human Embryonic Stem Cell Derived Cardiac Precursers

Feb 1, 2013
Cardiomyopathy is a broad term to describe the deterioration of function of the myocardium (heart muscle) that disrupts the heart’s ability to pump blood. Cardiomyopathy can be a serious chemotherapy-related cardiac dysfunction that can lead to chronic heart failure. The underlying mechanism of chemotherapeutics (anthracyclines, taxanes) and kinase inhibitor-induced cardiomyopathies is unclear. While certain compounds

Read more